What were Procter & Gamble Health Ltd's latest quarterly results?
Procter & Gamble Health Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +55.7% (stable)
- Revenue Growth YoY: +19.0%
- Operating Margin: 37.0% (volatile)
Procter & Gamble Health Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +18.6%Strong4w Streak
In , Procter & Gamble Health Ltd (Pharma - MNC bulk Drugs) is outperforming Nifty 500 with +18.6% relative strength. Fundamentals: Strong. On a 4-week streak.
Procter & Gamble Health Ltd Key Facts
- PE Ratio
- 31.6x
- Market Cap
- ₹10,346 Cr
- PAT Growth YoY
- +56%
- Revenue Growth YoY
- +19%
- OPM
- 37.0%
- RS vs Nifty 500
- +18.6%
PE: Mid ContractionStrong Opportunity
What's Happening
💎PE falling while earnings hold — value emerging
💪Debt reduced 40% YoY — balance sheet strengthening
🌐FII stake increased 0.6% this quarter
💰Trading 42% below estimated fair value — significant discount
Key Numbers
PAT Growth YoY
+56%
Stable
Revenue YoY
+19%
Stable
Operating Margin
37.0%
+1100 bps YoY
PE Ratio
31.6
Current Price
₹6,232
Dividend Yield
2.01%
Fundamental Score
69/100
Strong
3Y PAT CAGR
+28%
Market Cap
10.3K Cr
Valuation
Significantly Undervalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Procter & Gamble Health Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +19% | +11% | Stable |
| PAT (Net Profit) | +56% | +28% | Stable |
| OPM | 37.0% | +1100 bps | Volatile |
Other Top Pharma - MNC bulk Drugs Stocks Beating Nifty 500
Frequently Asked Questions: Procter & Gamble Health Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Procter & Gamble Health Ltd's profit growing or declining?
Procter & Gamble Health Ltd's profit is growing with an stable trend.
- PAT Growth YoY: +55.7% (latest quarter)
- PAT Growth QoQ: +21.8% (sequential)
- 3-Year PAT CAGR: +27.6%
- Trend: Stable — consistent growth pattern
What is Procter & Gamble Health Ltd's revenue growth trend?
Procter & Gamble Health Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +19.0%
- Revenue Growth QoQ: -1.1% (sequential)
- 3-Year Revenue CAGR: +10.6%
How is Procter & Gamble Health Ltd's operating margin trending?
Procter & Gamble Health Ltd's operating margin is volatile.
- Current OPM: 37.0%
- OPM Change YoY: +11.0% basis points
- OPM Change QoQ: +7.0% basis points
What is Procter & Gamble Health Ltd's 3-year profit and revenue CAGR?
Procter & Gamble Health Ltd's long-term compounding rates
- 3-Year Profit CAGR: +27.6%
- 3-Year Revenue CAGR: +10.6%
Is Procter & Gamble Health Ltd's growth accelerating or decelerating?
Procter & Gamble Health Ltd's earnings growth is stable with mixed signals on a sequential basis.
- YoY Acceleration: +70.0% bps
- Sequential Acceleration: +34.2% bps
What is Procter & Gamble Health Ltd's trailing twelve month (TTM) performance?
Procter & Gamble Health Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹328 Cr
- TTM PAT Growth: +30.7% YoY
- TTM Revenue: ₹1,000 Cr
- TTM Revenue Growth: +15.6% YoY
- TTM Operating Margin: 32.7%
Is Procter & Gamble Health Ltd overvalued or undervalued?
Procter & Gamble Health Ltd appears significantly undervalued based on our fair value analysis.
- Valuation Signal: Significantly Undervalued
- Current PE: 31.6x
- Price-to-Book: 19.7x
What is Procter & Gamble Health Ltd's current PE ratio?
Procter & Gamble Health Ltd's current PE ratio is 31.6x.
- Current PE: 31.6x
- Market Cap: 10.3K Cr
- Dividend Yield: 2.01%
How does Procter & Gamble Health Ltd's valuation compare to its history?
Procter & Gamble Health Ltd's current PE is 31.6x.
- Current PE: 31.6x
- Valuation Assessment: Significantly Undervalued
What is Procter & Gamble Health Ltd's price-to-book ratio?
Procter & Gamble Health Ltd's price-to-book ratio is 19.7x.
- Price-to-Book (P/B): 19.7x
- Book Value per Share: ₹316
- Current Price: ₹6232
Is Procter & Gamble Health Ltd a fundamentally strong company?
Procter & Gamble Health Ltd is rated Strong with a fundamental score of 69.28/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +19.0% (10% weight)
- PAT Growth YoY: +55.7% (10% weight)
- PAT Growth QoQ: +21.8% (10% weight)
- Margins stable (10% weight)
Is Procter & Gamble Health Ltd debt free?
Procter & Gamble Health Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹9 Cr
What is Procter & Gamble Health Ltd's return on equity (ROE) and ROCE?
Procter & Gamble Health Ltd's return ratios over recent years
- Jun 2024: ROCE 45.0%
- FY2025: ROCE 48.0%
- FY2026: ROCE 84.0%
Is Procter & Gamble Health Ltd's cash flow positive?
Procter & Gamble Health Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹338 Cr
- Free Cash Flow (FCF): ₹339 Cr
- CFO/PAT Ratio: 103% (strong cash conversion)
What is Procter & Gamble Health Ltd's dividend yield?
Procter & Gamble Health Ltd's current dividend yield is 2.01%.
- Dividend Yield: 2.01%
- Current Price: ₹6232
Who holds Procter & Gamble Health Ltd shares — promoters, FII, DII?
Procter & Gamble Health Ltd's shareholding pattern (Mar 2026)
- Promoters: 51.8%
- FII (Foreign): 6.2%
- DII (Domestic): 13.7%
- Public: 28.3%
Is promoter holding increasing or decreasing in Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 51.8% (Mar 2026)
- Previous Quarter: 51.8% (Dec 2025)
- Change: 0.00% (stable)
How long has Procter & Gamble Health Ltd been outperforming Nifty 500?
Procter & Gamble Health Ltd has been outperforming Nifty 500 for 4 consecutive weeks, indicating building momentum.
Is Procter & Gamble Health Ltd a new momentum entry or an established outperformer?
Procter & Gamble Health Ltd is an established outperformer with 4 weeks of consecutive Nifty 500 outperformance.
Is Procter & Gamble Health Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Procter & Gamble Health Ltd may be worth studying
- Earnings growing at +55.7% YoY
- Valuation: appears significantly undervalued
- Cash flow is positive — CFO ₹338 Cr
What is the investment thesis for Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +19.0% YoY
- Appears significantly undervalued
What is the future outlook for Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: stable
- Margin Trend: volatile
- Valuation: Significantly Undervalued
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.